Treatment-associated side effects have a significant impact on quality of life and treatment adherence. In the context of a life-long medical condition such as IBD, addressing potential tolerability issues becomes even more critical.
Drug tolerability, defined as the level of patient acceptance of adverse effects such as nausea, dry mouth, headache, diarrhea/constipation or mood change, has a significant impact on quality of life and treatment adherence. Addressing tolerability issue in the early phase of drug discovery is the cornerstone of Giiant’s research strategy. With the specific aim of bringing to patients a new therapeutic option for the treatment of IBD, Giiant Pharma has developed a gut-specific delivery platform. By targeting one single organ, improved tolerability arises from the lack of systemic exposure while sustained efficacy is ensured by the higher mucosal drug concentration at the site of inflammation.
GiiAnt, the Gastrointestinal-induced Anti-inflammatory technology, is a unique targeted delivery strategy that capitalize on the bacterial activity of the gut microbiota to bioactivate and specifically release the active principle in the lower bowel of the GI tract. This validated and proven strategy still represents the best way to improve the therapeutic index of a pharmacologic treatment. Although orally-delivered, Giiant’s drug candidates are not systemically absorbed while still achieving high drug concentration in the colonic area.
Ulcerative colitis and Crohn’s disease, the two main forms of inflammatory bowel disease (IBD), are both chronic relapsing diseases characterized by the inflammation of parts of the gastrointestinal tract.
Only in North America, more than 2 millions of people are suffering from this debilitating condition. Currently available medications alleviate inflammation but still do not prevent long term complications.
2021 Giiant Pharma All Rights Reserved